PMID- 22085338
OWN - NLM
STAT- MEDLINE
DCOM- 20120412
LR  - 20220321
IS  - 1651-226X (Electronic)
IS  - 0284-186X (Linking)
VI  - 51
IP  - 2
DP  - 2012 Feb
TI  - Risk profile of bevacizumab in patients with non-small cell lung cancer: a 
      meta-analysis of randomized controlled trials.
PG  - 151-6
LID - 10.3109/0284186X.2011.631579 [doi]
AB  - BACKGROUND: Severe adverse events (AEs) have been reported in cancer patients 
      treated with bevacizumab. Currently, safety of bevacizumab in patients with 
      non-small cell lung cancer (NSCLC) is not clear. We conducted a meta-analysis to 
      evaluate the risk profile of bevacizumab in NSCLC patients. METHODS: Relevant 
      trials were identified by searching databases and conference proceedings. Data on 
      treatment-related deaths and grade 3 or 4 AEs were extracted and pooled to 
      calculate relative risks (RRs) with 95% confidence interval (CI) for bevacizumab 
      compared with chemotherapy alone. RESULTS: A total of 2210 patients were included 
      in the analysis. Compared with chemotherapy alone, high-dosage (15 mg/kg) 
      bevacizumab was associated with an increased risk of treatment-related deaths (RR 
      = 2.04, 95% CI = 1.18-3.52), but not for low-dosage (7.5 mg/kg) group (RR = 1.20, 
      95% CI = 0.60-2.41). In addition, treatment with bevacizumab was associated with 
      several grade 3 or 4 AEs in patients with NSCLC, especially in high-dosage 
      bevacizumab group. CONCLUSION: The use of the bevacizumab increases the risk of 
      treatment-related deaths and several grade 3 or 4 AEs in patient with NSCLC. The 
      risk may be dose-dependent. Close monitoring and adequate management are 
      recommended to decrease severe AEs.
FAU - Cao, Chao
AU  - Cao C
AD  - Department of Respiratory Medicine, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Wang, Jianmiao
AU  - Wang J
FAU - Bunjhoo, Hansvin
AU  - Bunjhoo H
FAU - Xu, Yongjian
AU  - Xu Y
FAU - Fang, Huijuan
AU  - Fang H
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20111116
PL  - Sweden
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/*adverse effects
MH  - Antibodies, Monoclonal, Humanized/*adverse effects
MH  - Bevacizumab
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Treatment Outcome
EDAT- 2011/11/17 06:00
MHDA- 2012/04/13 06:00
CRDT- 2011/11/17 06:00
PHST- 2011/11/17 06:00 [entrez]
PHST- 2011/11/17 06:00 [pubmed]
PHST- 2012/04/13 06:00 [medline]
AID - 10.3109/0284186X.2011.631579 [doi]
PST - ppublish
SO  - Acta Oncol. 2012 Feb;51(2):151-6. doi: 10.3109/0284186X.2011.631579. Epub 2011 
      Nov 16.